Literature DB >> 3892220

Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors.

J P Johnson, J Moore, H A Austin, J E Balow, T T Antonovych, C B Wilson.   

Abstract

We have compared the effect of therapy with immunosuppression alone to immunosuppression plus plasma exchange on the clinical course and rate of disappearance of antibody in 17 patients with anti-glomerular basement membrane (anti-GBM) antibody-induced renal disease. Patients receiving immunosuppression (n = 9) and those receiving plasma exchange (n = 8) were similar in terms of entry clinical characteristics, pulmonary manifestations and complications associated with therapy. Rate of disappearance of anti-GBM antibody as estimated from serial estimates of antibody binding was significantly more rapid in patients receiving plasma exchange, and mean serum creatinine in these patients at end of therapy was half that of the patients receiving immunosuppression alone. Analysis of clinical and pathologic values at study entry, however, indicated that the percent of crescents on initial renal biopsy and entry serum creatinine correlated better with outcome than did therapeutic modality. Thus, though plasma exchange may offer some advantage over immunosuppression alone in the treatment of this disease, degree of pathologic involvement appears to be the major factor affecting outcome. Patients with low cresents (less than 30%) and well preserved function did well with either treatment, while patients with severe crescentic involvement and impaired glomerular filtration rate did poorly.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892220     DOI: 10.1097/00005792-198507000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  36 in total

Review 1.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

2.  Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study.

Authors:  Jicheng Lv; Yihe Yang; Hong Zhang; Wenfang Chen; Xiaoxia Pan; Zhiling Guo; Caili Wang; Shen Li; Jianrong Zhang; Jianchun Zhang; Lijun Liu; Sufang Shi; Suxia Wang; Min Chen; Zhao Cui; Nan Chen; Xueqing Yu; Minghui Zhao; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

3.  Anti-basement membrane antibody disease with severe pulmonary haemorrhage and normal renal function.

Authors:  A Tobler; E Schürch; H J Altermatt; V Im Hof
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

Review 4.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

Review 5.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

6.  Analysis of T cells and major histocompatibility complex class I and class II mRNA and protein content and distribution in antiglomerular basement membrane disease in the rabbit.

Authors:  C Eldredge; S Merritt; M Goyal; H Kulaga; T J Kindt; R Wiggins
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

7.  65-year-old woman with shortness of breath and dark urine.

Authors:  Ming Y Lim; Eddie L Greene
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

8.  Anti-glomerular basement membrane antibody-mediated glomerulonephritis due to glue sniffing.

Authors:  K E Bonzel; D E Müller-Wiefel; H Ruder; A M Wingen; R Waldherr; M Weber
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

Review 9.  The treatment of immune glomerular disease.

Authors:  D G Williams
Journal:  Springer Semin Immunopathol       Date:  1987

Review 10.  [Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

Authors:  R Birck; F J Van Der Woude
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.